D A Sclar

Summary

Affiliation: Washington State University
Country: USA

Publications

  1. ncbi Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, 99210 1495, USA
    Clin Drug Investig 32:e17-24. 2012
  2. ncbi α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:353-60. 2012
  3. ncbi Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA 99210 1495, USA
    Headache 52:198-203. 2012
  4. ncbi Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:139-44. 2012
  5. ncbi Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, WA 99164 6510, USA
    Int Clin Psychopharmacol 23:106-9. 2008
  6. ncbi Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Department of Health Policy and Administration, Washington State University, P O Box 646510, Pullman, WA 99164 6510, USA
    Gen Hosp Psychiatry 30:73-6. 2008
  7. ncbi Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions
    D A Sclar
    College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Depress Anxiety 8:121-7. 1998
  8. ncbi Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission
    David A Sclar
    Department of Health Policy and Administration, Washington State University, Pullman, WA 99164 6510, USA
    Drugs R D 6:149-56. 2005
  9. ncbi Economic appraisal of citalopram in the management of single-episode depression
    D A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    J Clin Psychopharmacol 19:47S-54S. 1999
  10. ncbi Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992-1997
    T L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Clin Ther 22:1575-89. 2000

Detail Information

Publications22

  1. ncbi Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, 99210 1495, USA
    Clin Drug Investig 32:e17-24. 2012
    ..Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD)...
  2. ncbi α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained
    David Alexander Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:353-60. 2012
    ..It has been shown that weekly or monthly infusion of human α-AT is effective in raising serum α-AT levels to desired levels (>80 mg/dL), with few, if any, adverse effects...
  3. ncbi Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Spokane, WA 99210 1495, USA
    Headache 52:198-203. 2012
    ....
  4. ncbi Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Spokane, WA, USA
    Clin Drug Investig 32:139-44. 2012
    ....
  5. ncbi Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, WA 99164 6510, USA
    Int Clin Psychopharmacol 23:106-9. 2008
    ..6 to 5.2 for blacks, and from 3.0 to 5.6 for Hispanics. It can be concluded that by 2003-2004, diagnostic and treatment rates were comparable among blacks and Hispanic, but were less than half the observed rates for whites...
  6. ncbi Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Department of Health Policy and Administration, Washington State University, P O Box 646510, Pullman, WA 99164 6510, USA
    Gen Hosp Psychiatry 30:73-6. 2008
    ..private) of U.S. patients aged 5-18 years who were hospitalized with a primary diagnosis of depression and (b) to discern the mean hospital length of stay and mean charge per day by payer type...
  7. ncbi Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions
    D A Sclar
    College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Depress Anxiety 8:121-7. 1998
    ..Herein, we review the pharmacoeconomic literature relative to antidepressant pharmacotherapy and identify issues for future inquiry...
  8. ncbi Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission
    David A Sclar
    Department of Health Policy and Administration, Washington State University, Pullman, WA 99164 6510, USA
    Drugs R D 6:149-56. 2005
    ....
  9. ncbi Economic appraisal of citalopram in the management of single-episode depression
    D A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    J Clin Psychopharmacol 19:47S-54S. 1999
    ..Multivariate models adjusted for nonrandom assignment to the initial pharmacotherapeutic option confirmed these findings. Further research over a longer time course is warranted...
  10. ncbi Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992-1997
    T L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Clin Ther 22:1575-89. 2000
    ....
  11. ncbi The need for an iterative process for assessing economic outcomes associated with SSRIs
    T L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, Washington, USA
    Pharmacoeconomics 18:205-14. 2000
    ..The portfolio of evidence to date indicates that the first-line use of SSRIs in the treatment of depression is clinically warranted, and represents value for money...
  12. ncbi Datapoints: trends in ADHD and stimulant use among adults: 1995-2002
    Linda M Robison
    Department of Health Policy and Administration, Washington State University, P.O. Box 646510, Pullman, Washington 99164-6510, USA
    Psychiatr Serv 56:1497. 2005
  13. ncbi Economic implications of sleep disorders
    Tracy L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, Washington, USA
    Pharmacoeconomics 28:1015-23. 2010
    ....
  14. ncbi Ethnicity/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia
    Megan N Willson
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USA
    Am J Cardiovasc Drugs 10:105-8. 2010
    ..Nevertheless, previous research suggests that there remain racial/ethnic disparities in the access to and quality of care for hyperlipidemia...
  15. ncbi Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychia
    Tracy L Skaer
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, Washington 99164 6510, USA
    Clin Ther 31:1478-87. 2009
    ..Tricyclic antidepressants (TCAs) were not recommended because of insufficient efficacy evidence, as well as adverse events...
  16. ncbi Rate of obesity in U.S. ambulatory patients with diabetes mellitus: a national assessment of office-based physician visits
    Joshua J Neumiller
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA 99217, United States
    Prim Care Diabetes 3:197-9. 2009
    ..S. National Ambulatory Medical Care Survey (NAMCS). Our findings indicate a significant proportion of U.S. ambulatory patients with DM present with obesity and greater clinical acuity than patients with DM alone...
  17. ncbi Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants
    Linda M Robison
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, Washington 99164 6510, USA
    CNS Drugs 16:129-37. 2002
    ....
  18. ncbi Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99
    Linda M Robison
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman 99164 6510, USA
    Int Clin Psychopharmacol 19:17-22. 2004
    ..5% of those aged 5-8 years. The reasons for the gender and age group differences discerned in this study require further investigation, as does the reason why 15.1% of children were receiving no treatment beyond the office-based visit...
  19. ncbi Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?
    Tracy L Skaer
    College of Pharmacy, Washington State University, PO Box 646510, Pullman, WA 99164 6510, USA
    Diabetes Educ 32:940-53. 2006
    ....
  20. ncbi The effects of soy milk and isoflavone supplements on cognitive performance in healthy, postmenopausal women
    L R Fournier
    Department of Psychology, Washington State University, Pullman, WA 99164 4820, USA
    J Nutr Health Aging 11:155-64. 2007
    ..Because of the health concerns related to hormone replacement therapy (HRT), alternative approaches to treat menopausal symptoms, such as nutritional supplements and/or diet containing isoflavones, are of interest...
  21. ncbi Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome
    David A Sclar
    Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, WA 99164 6510, USA
    Headache 48:126-9. 2008
    ..To discern the prevalence of concomitant use of a triptan and a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake inhibitor (SNRI) in the USA...
  22. ncbi Trends in oral antihyperglycemic and insulin use in the Nova Scotia senior population (1993-1999)
    Bridget A Morningstar
    Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia
    Can J Clin Pharmacol 9:123-9. 2002
    ..Further work is needed to determine the reasons for slow uptake of recommendations related to chlorpropamide and the effect of switches to human insulin and newer oral antihyperglycemics on patient outcomes and health care costs...